{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:05:00Z","timestamp":1762272300204,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T00:00:00Z","timestamp":1528329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81703618"],"award-info":[{"award-number":["81703618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12967-018-1533-4","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T09:57:38Z","timestamp":1528365458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics\/pharmacodynamics model"],"prefix":"10.1186","volume":"16","author":[{"given":"Taotao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ti","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin\u2019e","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5619-0788","authenticated-orcid":false,"given":"Yalin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,7]]},"reference":[{"key":"1533_CR1","first-page":"w14281","volume":"146","author":"Y Schmiedel","year":"2016","unstructured":"Schmiedel Y, Zimmerli S. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia. Swiss Med Wkly. 2016;146:w14281.","journal-title":"Swiss Med Wkly."},{"issue":"8","key":"1533_CR2","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1182\/blood-2011-04-351601","volume":"119","author":"A Bergeron","year":"2012","unstructured":"Bergeron A, Porcher R, Sulahian A, de Bazelaire C, Chagnon K, Raffoux E, Vekhoff A, Cornet M, Isnard F, Brethon B, et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood. 2012;119(8):1831\u20137 (quiz 956).","journal-title":"Blood."},{"issue":"10","key":"1533_CR3","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1128\/AAC.00425-10","volume":"54","author":"AH Groll","year":"2010","unstructured":"Groll AH, Silling G, Young C, Schwerdtfeger R, Ostermann H, Heinz WJ, Gerss J, Kolve H, Lanvers-Kaminsky C, Vieira Pinheiro JP, et al. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother. 2010;54(10):4143\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1533_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.blre.2009.11.003","volume":"24","author":"L Pagano","year":"2010","unstructured":"Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev. 2010;24(2):51\u201361.","journal-title":"Blood Rev"},{"issue":"3","key":"1533_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.diagmicrobio.2014.03.020","volume":"79","author":"SC Heng","year":"2014","unstructured":"Heng SC, Chen SC, Morrissey CO, Thursky K, Manser RL, De Silva HD, Halliday CL, Seymour JF, Nation RL, Kong DC, Slavin MA. Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies. Diagn Microbiol Infect Dis. 2014;79(3):322\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"1533_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u201360.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1533_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ1194","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1\u201350.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1533_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1128\/CMR.00055-08","volume":"22","author":"TR Dagenais","year":"2009","unstructured":"Dagenais TR, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev. 2009;22(3):447\u201365.","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"1533_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649\u201363.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1533_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","volume":"102","author":"F Tissot","year":"2017","unstructured":"Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Florl C, Calandra T, Viscoli C, Herbrecht R. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433\u201344.","journal-title":"Haematologica"},{"issue":"10","key":"1533_CR11","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3324\/haematol.2009.020073","volume":"95","author":"C Cordonnier","year":"2010","unstructured":"Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, Pigneux A, Cornely OA, Ullmann AJ, Bofarull RM, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762\u20138.","journal-title":"Haematologica"},{"issue":"7","key":"1533_CR12","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1469-0691.2009.02913.x","volume":"15","author":"WW Hope","year":"2009","unstructured":"Hope WW, Drusano GL. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin Microbiol Infect. 2009;15(7):602\u201312.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"1533_CR13","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1128\/AAC.50.5.1878-1880.2006","volume":"50","author":"B Capitano","year":"2006","unstructured":"Capitano B, Potoski BA, Husain S, Zhang S, Paterson DL, Studer SM, McCurry KR, Venkataramanan R. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother. 2006;50(5):1878\u201380.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1533_CR14","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1128\/AAC.00942-13","volume":"57","author":"SC Heng","year":"2013","unstructured":"Heng SC, Snell GI, Levvey B, Keating D, Westall GP, Williams TJ, Whitford H, Nation RL, Slavin MA, Morrissey O, Kong DC. Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients. Antimicrob Agents Chemother. 2013;57(9):4581\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1533_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1128\/CMR.00014-09","volume":"22","author":"SJ Park","year":"2009","unstructured":"Park SJ, Mehrad B. Innate immunity to Aspergillus species. Clin Microbiol Rev. 2009;22(4):535\u201351.","journal-title":"Clin Microbiol Rev"},{"issue":"Pt 8","key":"1533_CR16","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1242\/jcs.00329","volume":"116","author":"JA Wasylnka","year":"2003","unstructured":"Wasylnka JA, Moore MM. Aspergillus fumigatus conidia survive and germinate in acidic organelles of A549 epithelial cells. J Cell Sci. 2003;116(Pt 8):1579\u201387.","journal-title":"J Cell Sci"},{"issue":"3","key":"1533_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/fcp.12262","volume":"31","author":"T Wang","year":"2017","unstructured":"Wang T, Yang Q, Chen L, Li Y, Meng T, Wang Y, Zhang T, Lei J, Xing J, Dong Y. Uptake and efflux kinetics, and intracellular activity of voriconazole against Aspergillus fumigatus in human pulmonary epithelial cells: a new application for the prophylaxis and early treatment of invasive pulmonary aspergillosis. Fundam Clin Pharmacol. 2017;31(3):311\u20138.","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"1533_CR18","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","volume":"44","author":"T Wang","year":"2014","unstructured":"Wang T, Zhu H, Sun J, Cheng X, Xie J, Dong H, Chen L, Wang X, Xing J, Dong Y. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014;44(5):436\u201342.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"1533_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jac\/dkt369","volume":"69","author":"T Wang","year":"2014","unstructured":"Wang T, Chen S, Sun J, Cai J, Cheng X, Dong H, Wang X, Xing J, Dong W, Yao H, Dong Y. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chemother. 2014;69(2):463\u201370.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1533_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dki079","volume":"55","author":"JW Mouton","year":"2005","unstructured":"Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55(5):601\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1533_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/jac\/dkh511","volume":"55","author":"RG Masterton","year":"2005","unstructured":"Masterton RG, Kuti JL, Turner PJ, Nicolau DP. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother. 2005;55(1):71\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1533_CR22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1365-2141.2004.05140.x","volume":"126","author":"J Maertens","year":"2004","unstructured":"Maertens J, Theunissen K, Verbeken E, Lagrou K, Verhaegen J, Boogaerts M, Eldere JV. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol. 2004;126(6):852\u201360.","journal-title":"Br J Haematol"},{"issue":"9","key":"1533_CR23","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/infdis\/jir023","volume":"203","author":"SJ Howard","year":"2011","unstructured":"Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis. 2011;203(9):1324\u201332.","journal-title":"J Infect Dis"},{"issue":"3","key":"1533_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1086\/510535","volume":"195","author":"WW Hope","year":"2007","unstructured":"Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, Kasai M, Mickiene D, Sein T, Peter J, et al. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis. 2007;195(3):455\u201366.","journal-title":"J Infect Dis"},{"issue":"3","key":"1533_CR25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/infdis\/jis372","volume":"206","author":"AR Jeans","year":"2012","unstructured":"Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Majithiya JB, Lass-Florl C, Cuenca-Estrella M, Arendrup MC, Warn PA, Hope WW. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. J Infect Dis. 2012;206(3):442\u201352.","journal-title":"J Infect Dis"},{"issue":"10","key":"1533_CR26","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/infdis\/jit358","volume":"208","author":"P Campoli","year":"2013","unstructured":"Campoli P, Perlin DS, Kristof AS, White TC, Filler SG, Sheppard DC. Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis. J Infect Dis. 2013;208(10):1717\u201328.","journal-title":"J Infect Dis"},{"issue":"2","key":"1533_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/lt.24365","volume":"22","author":"J Balogh","year":"2016","unstructured":"Balogh J, Gordon Burroughs S, Boktour M, Patel S, Saharia A, Ochoa RA, McFadden R, Victor DW, Ankoma-Sey V, Galati J, et al. Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients. Liver Transpl. 2016;22(2):163\u201370.","journal-title":"Liver Transpl"},{"issue":"4","key":"1533_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/ajh.23388","volume":"88","author":"JN Barreto","year":"2013","unstructured":"Barreto JN, Beach CL, Wolf RC, Merten JA, Tosh PK, Wilson JW, Hogan WJ, Litzow MR. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole. Am J Hematol. 2013;88(4):283\u20138.","journal-title":"Am J Hematol"},{"issue":"3","key":"1533_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.diagmicrobio.2006.01.018","volume":"55","author":"GT Siwek","year":"2006","unstructured":"Siwek GT, Pfaller MA, Polgreen PM, Cobb S, Hoth P, Magalheas-Silverman M, Diekema DJ. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis. 2006;55(3):209\u201312.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"1533_CR30","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.bbmt.2013.12.117","volume":"20","author":"Y Hayashi","year":"2014","unstructured":"Hayashi Y, Kanda Y, Nakamae H, Kanamori H, Ohashi K, Hidaka M, Yano S, Hatanaka K, Kohno A, Moriuchi Y. Voriconazole vs. itraconazole for antifungal prophylaxis in patients with GVHD: a randomized trial. Biol Blood Marrow Transpl. 2014;20(2):S91.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"Suppl 2","key":"1533_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1469-0691.2012.03772.x","volume":"18","author":"Y Hicheri","year":"2012","unstructured":"Hicheri Y, Cook G, Cordonnier C. Antifungal prophylaxis in haematology patients: the role of voriconazole. Clin Microbiol Infect. 2012;18(Suppl 2):1\u201315.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"1533_CR32","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1097\/INF.0b013e3182a74233","volume":"32","author":"GM Maron","year":"2013","unstructured":"Maron GM, Hayden RT, Rodriguez A, Rubnitz JE, Flynn PM, Shenep JL, Knapp KM. Voriconazole prophylaxis in children with cancer: changing outcomes and epidemiology of fungal infections. Pediatr Infect Dis J. 2013;32(12):e451\u20135.","journal-title":"Pediatr Infect Dis J."},{"key":"1533_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2016.05.002","author":"H Sano","year":"2016","unstructured":"Sano H, Kobayashi R, Hori D, Kishimoto K, Suzuki D, Yasuda K, Kobayashi K. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia. J Microbiol Immunol Infect. 2016. \n                    https:\/\/doi.org\/10.1016\/j.jmii.2016.05.002\n                    \n                  .","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"1533_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00520-009-0783-3","volume":"19","author":"GN Mattiuzzi","year":"2011","unstructured":"Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011;19(1):19\u201326.","journal-title":"Support Care Cancer"},{"issue":"3","key":"1533_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1600-0609.2009.01367.x","volume":"84","author":"A Torres","year":"2010","unstructured":"Torres A, Serrano J, Rojas R, Martin V, Martin C, Tabares S, Molina JR, Capote M, Martinez F, Gomez P, Sanchez-Garcia J. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. Eur J Haematol. 2010;84(3):271\u20133.","journal-title":"Eur J Haematol"},{"issue":"1","key":"1533_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.00133-06","volume":"52","author":"S Kiem","year":"2008","unstructured":"Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother. 2008;52(1):24\u201336.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1533_CR37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","volume":"40","author":"S Trifilio","year":"2007","unstructured":"Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, Winter J, Tallman M, Pi J, Mehta J. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transpl. 2007;40(5):451\u20136.","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"1533_CR38","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1128\/JCM.00925-15","volume":"53","author":"F Lamoth","year":"2015","unstructured":"Lamoth F, Alexander BD. Comparing Etest and broth microdilution for antifungal susceptibility testing of the most-relevant pathogenic molds. J Clin Microbiol. 2015;53(10):3176\u201381.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"1533_CR39","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1128\/AAC.05219-11","volume":"56","author":"D Mitsani","year":"2012","unstructured":"Mitsani D, Nguyen MH, Shields RK, Toyoda Y, Kwak EJ, Silveira FP, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Clancy CJ. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother. 2012;56(5):2371\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1533_CR40","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1128\/AAC.00637-11","volume":"55","author":"P Campoli","year":"2011","unstructured":"Campoli P, Al Abdallah Q, Robitaille R, Solis NV, Fielhaber JA, Kristof AS, Laverdiere M, Filler SG, Sheppard DC. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother. 2011;55(12):5732\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1533_CR41","first-page":"2419","volume":"8","author":"XY Xu","year":"2016","unstructured":"Xu XY, Chen F, Sun H, Chen C, Zhao BL. Important factors mediates the adhesion of Aspergillus fumigatus to alveolar epithelial cells with E-cadherin. Am J Transl Res. 2016;8(5):2419\u201325.","journal-title":"Am J Transl Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1533-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-018-1533-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1533-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T19:09:52Z","timestamp":1559848192000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-018-1533-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1533"],"URL":"https:\/\/doi.org\/10.1186\/s12967-018-1533-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2018,6,7]]},"assertion":[{"value":"19 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"157"}}